Compare GRDX & RENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRDX | RENX |
|---|---|---|
| Founded | N/A | 2021 |
| Country | United Kingdom | United States |
| Employees | 2 | 38 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 6.7M |
| IPO Year | N/A | N/A |
| Metric | GRDX | RENX |
|---|---|---|
| Price | $2.06 | $2.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 77.8K | ★ 5.5M |
| Earning Date | 05-14-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.87 | $0.09 |
| 52 Week High | $5.30 | $3.48 |
| Indicator | GRDX | RENX |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 71.88 |
| Support Level | $1.99 | $0.12 |
| Resistance Level | $2.60 | $3.48 |
| Average True Range (ATR) | 0.21 | 0.41 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 18.84 | 79.92 |
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
RenX Enterprises Corp is a real estate development and environmental solutions company. It is focused on the direct acquisition and indirect investment in properties across the United States that are intended for development into green single-family or multifamily housing projects. The company also focuses on the monetization of its real estate assets. It processes source-separated green waste and is expanding into the production of sustainable, high-margin potting media and soil substrates through advanced milling technology.